Comparison of meglumine antimoniate versus miltefosine in the treatment of new world cutaneous leishmaniasis: a systematic review and meta-analysis.

ABSTRACT:

Background

Cutaneous Leishmaniasis (CL) affects up to 1.2 million people annually, mainly in resource-limited regions. Meglumine antimoniate, the standard treatment, is limited by systemic toxicity, injectable administration, and increasing resistance. Miltefosine, an oral alternative, offers practical advantages, although comparative efficacy and safety data remain inconsistent.

Objective

To compare the efficacy and safety of miltefosine versus meglumine antimoniate for New World CL.

Methods

The authors systematically searched PubMed, Embase, Scopus, and the Cochrane Library for randomized controlled trials directly comparing miltefosine and meglumine antimoniate. Risk Ratios (RRs) with 95% Confidence Intervals (95% CIs) were calculated using random-effects models. H

SUBMITTER: Vieira ACP 

PROVIDER: S-EPMC12813531 | biostudies-literature | 2026 Jan

REPOSITORIES: biostudies-literature